SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AMC Robotics Corp. engages in developing and deploying AI-enabled robotics and smart security solutions, especially for warehouse automation, enterprise security, robotics patrol/incident-response and logistics automation. The company is headquartered in New York, NY.

AMC Robotics Corp.

AMCI is trending as traders discuss its potential for a short squeeze and speculate on price movements, with some expressing concerns about it being a pump and dump. The stock's low float and recent volatility are key points of discussion, with community members comparing it to other robotics plays. Some traders are also eyeing related tickers, anticipating similar potential moves.

Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. It focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The company is founded by Paul A. Hopper in 2021 headquartered Carlton, Australia.

Radiopharm Theranostics Ltd - ADR

RADX is trending due to discussions around a potential short squeeze and high volatility, fueled by the company's recent activity and a relatively small float. Community members are debating fair value and if it is worth accumulating, and some traders are highlighting technical indicators. The company is a clinical-stage biopharmaceutical firm focused on developing innovative oncology radiopharmaceuticals.

ARB IOT Group Ltd. is a holding company that engages in the provision of solutions for the integration of IoT systems and devices. It operates through the Internet of Things and Investment Holding and Others segments. The company was founded on March 1, 2022 and is headquartered in Singapore.

ARB IOT Group Ltd

ARBB is trending due to community members discussing a potential short squeeze driven by the stock's low float. Traders are actively monitoring key price levels, anticipating a run to higher prices, with some comparing it to previous runners. Intense volatility has led to multiple trading halts, adding to the speculative buzz.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray is trending amid speculation surrounding potential marijuana rescheduling, driven by rumors of an upcoming announcement and a possible executive order. Community discussions revolve around the potential impact on the cannabis sector, tax implications, and Tilray's future market position, with some traders anticipating a significant short squeeze if the rescheduling occurs.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences is trending as the community discusses the potential for a short squeeze and the impact of preliminary data showing an 80% reduction in breast cancer recurrence rates. Community members are debating the significance of the news, speculating about a potential buyout, and analyzing short interest data. The stock is seen as a biotech microcap with a history of explosive moves, making it a high-risk, high-reward play.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNow's stock is trending amid reports of a potential acquisition of cybersecurity firm Armis, sparking debate about the deal's price tag and strategic fit. While some investors are wary of the cost and integration risks, analysts remain optimistic about the long-term upside of strengthening ServiceNow's platform with cybersecurity capabilities. The community is weighing the short-term volatility against the potential for long-term gains in the cybersecurity space.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending, fueled by Wedbush's reaffirmed bullish outlook and robotaxi optimism, despite concerns about valuation and declining EV sales; the community is buzzing about the potential for new all-time highs and debates the impact of AI and SpaceX on the stock, with both bulls and bears digging in.

Artiva Biotherapeutics, Inc. operates as a biotechnology company for the treatment of hematologic cancers. It offers NK cell therapies for cancer. The company was founded by Thomas J. Farrell in 2019 and is headquartered in San Diego, CA.

Artiva Biotherapeutics Inc

ARTV is trending after receiving FDA Fast Track designation for its AlloNK therapy in refractory rheumatoid arthritis, a significant step for its clinical development. The community is discussing the potential impact on the autoimmune market and the possibility of future data readouts and clinical responses. Bullish sentiment is fueled by analyst upgrades and price target increases, though some caution against potential dilution and profit-taking.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is trending downwards, sparking debates about its viability and potential for a delisting pump. Community members are expressing frustration with its performance relative to Bitcoin and other altcoins, with some labeling it a scam due to perceived lack of utility and the performance of the Janction token. Despite the negative sentiment, some bulls remain hopeful, citing ongoing development, partnerships, and the potential for a turnaround in 2026.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and the FC SAN business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

AVGO is trending downwards as investors express concern over potential margin compression despite strong AI-driven revenue growth and a large order backlog. The community is debating whether this dip is a buying opportunity or a sign of broader tech sector vulnerability, with some pointing to analysts' price target increases as a reason for optimism. Discussions also include comparing AVGO's valuation to other tech giants like META and the potential impact of AI infrastructure spending.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The company highlighted an 80% recurrence rate reduction in the open-label non-HLA-A*02 arm of the Phase III clinical trial.&nbsp;</li><li>The company noted that the latest observation trended similarly to its Phase IIb trial results and hazard ratio.</li></ul>Greenwich LifeSciences, Inc.’s (GLSI) shares soared in premarket trading on Monday after the company announced positive results from its phase III clinical trial, FLAMINGO-01, evaluating an immunotherapy to prevent breast cancer recurrences.Greenwich highlighted about an 80% recurrence rate reduction in the open-label non-HLA-A*02 arm of the Phase III clinical trial.Shares of <a href="https://stocktwits.com/symbol/GLSI">GLSI</a> were up over 86% premarket at the time of writing.<h2 class="st-heading-2">Trial Details</h2>The company noted that the latest observation trended similarly to its Phase IIb trial results and hazard ratio, where the patients were treated, and breast cancer recurrences were reduced up to 80% compared to a 20-50% reduction in recurrence rate by other approved products.“Despite these being preliminary results that will mature and can change with time, seeing a reduction in expected recurrence rates that is trending towards a low HR of 0.2, which represents an 80% reduction in recurrence rate, is very encouraging and which is why along with the similarly promising safety and immune response data to date, we will seek to continue to treat non-HLA-A*02 patients in a placebo controlled manner in the study," said CEO Snehal Patel.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, GLSI was the second-most trending stock on Monday morning. The retail sentiment around GLSI continued to trend in the ‘extremely bullish’ territory compared to ‘bullish’ a month ago, while message volume has remained ‘extremely high’ at the time of writing.<figure class="image"><img style="aspect-ratio:1279/145;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_15_at_5_07_16_PM_png_76f022ac17.webp" alt="Retail sentiment for GLSI at the time of writing was 'extremely bullish' and message volume was 'extremely high'." width="1279" height="145"></figure>One Stocktwits user said they would be watching the stock all day, indicating their bullish stance on the company.<stembedurl>https://stocktwits.com/Rolltide2020/message/639156747</stembedurl>Shares of GLSI are down over 16% over the last year.For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

Mammogram imagery, regular mammogram on the left, and contrast enhanced mammogram on the right, on Thursday, Sept. 26, 2024 in Houston. (Brett Coomer/Houston Chronicle via Getty Images)

Why Is GLSI Stock Rising Today?

Greenwich LifeSciences shares surged following the company’s announcement of positive results from its phase III clinical trial, FLAMINGO-01. 

Why Is GLSI Stock Rising Today? 

Equity

Greenwich LifeSciences shares surged following the company’s announcement of positive results from its phase III clinical trial, FLAMINGO-01. 


Noble Financial Issues Pessimistic Outlook for GLSI Earnings

Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Free Report) - Equities research analysts at Noble Financial decreased their FY2025 EPS estimates for Greenwich LifeSciences in a research note issued on...

Insider Buying: Greenwich LifeSciences (NASDAQ:GLSI) CEO Purchases $38,502.00 in Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) CEO Snehal Patel bought 4,600 shares of Greenwich LifeSciences stock in a transaction that occurred on Tuesday, November 25th. The stock...

Greenwich LifeSciences (NASDAQ:GLSI) Releases Earnings Results, Meets Expectations

Greenwich LifeSciences (NASDAQ:GLSI - Get Free Report) released its earnings results on Friday. The company reported ($0.30) EPS for the quarter, hitting the consensus estimate of ($0.30...

Insider Buying: Greenwich LifeSciences (NASDAQ:GLSI) CEO Purchases 10,600 Shares of Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) CEO Snehal Patel purchased 10,600 shares of the stock in a transaction on Friday, November 7th. The shares were acquired at an average...

Greenwich LifeSciences (NASDAQ:GLSI) CEO Buys $89,358.00 in Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) CEO Snehal Patel purchased 10,600 shares of the company's stock in a transaction on Friday, November 7th. The shares were purchased at an...

Traders are reacting to preliminary FLAMINGO-01 trial data showing an estimated 80% reduction in breast cancer recurrence rates for GLSI-100, fueling optimism about its medical and market potential.

Intense chatter suggests high short interest and a low float, leading many to believe a significant short squeeze is imminent.

Speculation is rife about a potential acquisition, with traders anticipating major pharmaceutical interest and significant valuations based on the recent clinical data.

Despite positive news, the stock experienced a pullback from pre-market highs, causing frustration for some bulls while others see it as an opportunity to buy the dip.

GLSI
Greenwich LifeSciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest GLSI News

GLSIGreenwich LifeSciences Inc